Antipruritic armamentarium with short term nutritional support solution involving slymarin and curcumin for atopic dermatitis in dogs

Öz

Well-known medicinal plants Curcuma longa (turmeric) and Slybium marianum (slymarin) have growing interest for its therapeutic anti-inflammatory and antipruritic actions. The present researcher group hypothesized that commercially available oral/topical solution involving C. Longa and Slybium marianum combination will significantly decrease the pruritus scores after short-term (1 week of twice-daily) oral treatment in dogs with atopic dermatitis (AD). Twenty-six dogs with AD, diagnosis based on alergen specific Ig E levels, CADESI-04 scores and clinical signs involving pruritus, previously not received any treatment. Evaluations included Owner Pruritus VAS score (OPVAS), Veterinarian Dermatitis VAS score (VDVAS) and in vitro allergy testing. The mean day 0 OPVAS were similar (p>0.05) between the Silifort paste treatment groups (STG) (range 2-10) and placebo control dogs (CG) (range 2-10), respectively. The mean OPVAS continued to gradually decrease over the remaining 6 days of study in TG (p<0.0001). At day 7, the mean OPVAS had decreased for the STG to 0.93 cm. The reduction in OPVAS for CG after 7 days was only 1.81 cm. The mean day 0 VDVAS were similar (p>0.05) between the STG (range 2-10) and CG (range 2-10), respectively. At day 7, the mean VDVAS for STG had decreased to 1 cm and for the placebo CG to 5.2 cm (p<0.0001). The VDVAS in STG were significantly lower compared to STG on day 7 (p<0.0001). The present study supports a potential benefit of Silifort paste for short-term relieving itching sensation. This treatment modality might replace immunosuppressive applications, with its anti-inflammatory, anti-infectious and antioxidant formulation.

Anahtar Kelimeler

• curcumin
• dog
• pruritis
• slymarin

Kaynakça

1. 1. Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittel-Forschung. 1974;24(4):466-471.
2. 2. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology. 1999;30:1099-104.
3. 3. Dorjay K, Arif T, Adil M. Silymarin: An interesting modality in dermatological therapeutics. Indian J Dermatol Venereol Leprol. 2018;84(2):238.
4. 4. Sharma RA, McLelland HR, Hill KA, Ireson CR. Euden SA, Manson MM, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7:1894-1900.
5. 5. Garcea G, Berry DP, Jones DJL, Singh R, Dennison AR, Farmer PB, Gescher AJ. Consumption of the putative chemopreventative agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamics consequences. Cancer Epidemiol Biomarkers Prev. 2005;14:120-125.
6. 6. Siviero A, Gallo E, Maggini V, Gori L, Mugelli A, Firenzuoli F, Vannacci A. Curcumin, a golden spice with low bioavailability. J Herbal Med 2015;5:57-70.
7. 7. Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, Stegemann MR. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114.
8. 8. Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA, et al.. Interleukin‐31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-e12.

9. 9. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine. 2005;12(6-7):445-452.
10. 10. Sandur SK, Ichikawa H, Pandey MK, Kunnumakkara AB, Sung B, Sethi G, et al. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med. 2007;43(4):568-580.
11. 11. Aggarwal B, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363-398.
12. 12. Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett. 1994;341:19-22.
13. 13. Heng MC, Song MK, Heng MK. Elevated phosphorylase kinase activity in psoriatic epidermis: correlation with increased phosphorylation and psoriatic activity. Br J Dermatol. 1994;130:298-306.
14. 14. Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000;143:937-949.
15. 15. Heng MC. Signaling pathways targeted by curcumin in acute and chronic injury: burns and photodamaged skin. Int J Dermatol. 2013;52:531-543.
16. 16. Heng MC. Wound healing in adult skin: aiming for perfect regeneration. Int J Dermatol. 2011;50:1058-1066.
17. 17. Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: Clinical and instrumental evaluation. J Cosmet Dermatol. 2008;7:8-14.
18. 18. Kang JS, Yoon WK, Han MH, Lee H, Lee CW, Lee KH, et al. Inhibition of atopic dermatitis by topical application of silymarin in NC/Nga mice. Int Immunopharmacol. 2008;8:1475-80.
19. 19. Mady FM, Essa H, El-Ammawi T, Abdelkader H, Hussein AK. Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Des Devel Ther. 2016;10:1101-10.